Company intelligence / Profile preview

Innodem Neurosciences

Montreal, Quebec, Canadainnodemneurosciences.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s flagship product ETNA™‑MS received Health Canada approval in March 2024 as a class II software as a medical device for use in tracking multiple sclerosis progression. Preliminary clinical trial results have been peer-reviewed and published. Ongoing observational trials are validating the technology across additional neurodegenerative and mental disorders. Early data show that eye movement parameters captured by the system correlate with established clinical scales of disease status and cognition.

Therapeutic areas: OncologyNeurology
Modalities: DeviceSoftware as a medical device (SaMD)Artificial intelligence-based diagnosticsDigital biomarker platform
Industry: Digital Health Medical Devices

Drug pipeline

1 asset

ETNA-MS

Commercial

Indications: Multiple sclerosis

Partnerships

Novartis Pharmaceuticals Canada Inc.

Beyond the preview

Go deeper on Innodem Neurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innodem Neurosciences.

Explore the full profile